Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ: SNY )

47.71 +0.21 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,486,786
Open 46.92
Bid (Size) 47.72 (6)
Ask (Size) 47.74 (62)
Prev. Close 47.50
Today's Range 46.89 - 47.90
52wk Range 45.22 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 4.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
Why Cytokinetics Stock Was a Nearly 5% Winner Today
Via The Motley Fool

Performance

YTD
-4.58%
-4.58%
1 Month
-0.56%
-0.56%
3 Month
-16.92%
-16.92%
6 Month
-2.57%
-2.57%
1 Year
-2.11%
-2.11%

More News

Read More
In a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why NASDAQ:SNY qualifies as a good dividend investing stock.
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY.
Via Chartmill
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Via Investor's Business Daily
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Via Benzinga
Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
Via Benzinga
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
Via Benzinga
Topics Government
Exposures Political Product Safety
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
Via The Motley Fool
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
NVIDIA Invested in These 2 AI Stocks, Should You?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Bird Flu Found In Raw Milk Leads To Recall In California
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Via Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.